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Overexpression of Cyclin E1 or Cdc25A leads to
replication stress, mitotic aberrancies, and
increased sensitivity to replication checkpoint
inhibitors
Yannick P. Kok1, Sergi Guerrero Llobet1, Pepijn M. Schoonen1, Marieke Everts1, Arkajyoti Bhattacharya1,
Rudolf S. N. Fehrmann1, Nathalie van den Tempel 1 and Marcel A. T. M. van Vugt 1
Abstract
Oncogene-induced replication stress, for instance as a result of Cyclin E1 overexpression, causes genomic instability
and has been linked to tumorigenesis. To survive high levels of replication stress, tumors depend on pathways to deal
with these DNA lesions, which represent a therapeutically actionable vulnerability. We aimed to uncover the
consequences of Cyclin E1 or Cdc25A overexpression on replication kinetics, mitotic progression, and the sensitivity to
inhibitors of the WEE1 and ATR replication checkpoint kinases. We modeled oncogene-induced replication stress using
inducible expression of Cyclin E1 or Cdc25A in non-transformed RPE-1 cells, either in a TP53 wild-type or TP53-mutant
background. DNA fiber analysis showed Cyclin E1 or Cdc25A overexpression to slow replication speed. The resulting
replication-derived DNA lesions were transmitted into mitosis causing chromosome segregation defects. Single cell
sequencing revealed that replication stress and mitotic defects upon Cyclin E1 or Cdc25A overexpression resulted in
genomic instability. ATR or WEE1 inhibition exacerbated the mitotic aberrancies induced by Cyclin E1 or Cdc25A
overexpression, and caused cytotoxicity. Both these phenotypes were exacerbated upon p53 inactivation. Conversely,
downregulation of Cyclin E1 rescued both replication kinetics, as well as sensitivity to ATR and WEE1 inhibitors. Taken
together, Cyclin E1 or Cdc25A-induced replication stress leads to mitotic segregation defects and genomic instability.
These mitotic defects are exacerbated by inhibition of ATR or WEE1 and therefore point to mitotic catastrophe as an
underlying mechanism. Importantly, our data suggest that Cyclin E1 overexpression can be used to select patients for
treatment with replication checkpoint inhibitors.
Introduction
A common hallmark of cancer is the acquisition of
genomic gains and losses as well as complex genomic re-
arrangements, collectively termed genomic instability1.
Genomic instability drives intra-tumor heterogeneity,
which is an important factor underlying therapy failure2.
Stalling or slowing of replication, commonly referred to as
‘replication stress’, is increasingly considered to be an
important factor in fueling genomic instability in can-
cer3,4. Although there are various factors that induce
replication stress, a common cause in the context of
cancer is the increased activity or elevated expression of
oncogenes4–6.
Amplification of CCNE1 (encoding for Cyclin E1) is
frequently observed in genomically instable tumors,
including high-grade serous ovarian cancer and triple
negative breast cancer (TNBC)7–12, and has been asso-
ciated with a poor prognosis in these and various other
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tumor types13–16. CCNE1 amplification has been linked to
induction of replication stress, by causing collisions
between the replication and transcription machineries17,
and by triggering aberrant firing of replication origins,
which subsequently leads to depletion of the nucleotide
pool3,17. Combined, these effects can lead to stalling or
collapse of replication forks4. Oncogene-induced replica-
tion stress triggers a DNA damage response, with ensuing
genetic pressure to inactivate TP536. In good agreement
with these observations, Cyclin E1 overexpression was
demonstrated to exclusively induce genome instability in
tumors lacking functional p5318–20.
Multiple oncogenic events were shown to exert their
effects on DNA replication through direct or indirect ele-
vation of Cyclin-dependent kinase-2 (CDK2) activity21–24.
CDK2 activity is important in regulating the ‘firing’ of
replication origins17,25,26, and is primarily controlled by the
abundance of its Cyclin partner. Indeed, overexpression of
Cyclin E1 elevates CDK2 activity26. Importantly, CDK2
activity—determined by inhibitory phosphorylation of
Tyr1527—is catalyzed by the WEE1 kinase28,29, and can be
removed by the Cdc25A phosphatase30. In line with this
notion, overexpression of Cdc25A has been shown to result
in CDK2 hyperactivation27. Consequently, overexpression
of either CCNE1 or Cdc25A leads to aberrant firing of
replication origins and triggers a replication stress
response17.
Since replication stress hampers cell growth, cancers
harboring oncogene-induced replication stress have
apparently adapted to cope with replication stress. In
order to find better treatments for tumors with oncogene-
induced replication stress, it could be of great clinical
interest to target pathways that allow tumors to deal with
replication stress. Particularly interesting in this context
are cell cycle checkpoint kinases. Previously, tumor cells
with genome instability due to defective homologous
recombination were shown to depend on the ATR and
WEE1 replication checkpoint kinases for their survi-
val31,32. Furthermore, lymphomas driven by MYC ampli-
fication—which triggers profound replication stress—
were shown to be highly sensitive to CHK1 inhibition33.
In order to optimally implement cell cycle checkpoint
inhibitors in cancer treatment, and identify patients who
benefit from such treatments, it is essential to understand
how cancer cells deal with replication stress, and uncover
the mechanisms underlying checkpoint kinase inhibitor-
mediated cytotoxicity in cancer cells.
It is increasingly apparent that the resolution of repli-
cation stress is highly complex and not restricted to S-
phase. Indeed, resolving late-stage replication inter-
mediates was observed even when cells had already
entered mitosis34,35. In line with these observations, our
recent data underscored the notion that PARP inhibitor-
induced replication-mediated DNA lesions are
transmitted into mitosis, and cause chromosome segre-
gation defects and mitotic failure32. Whether these find-
ings hold true for other sources of replication stress is
currently unknown. In this study, we assessed whether
oncogene-induced replication stress as a result of Cyclin
E1 or Cdc25A overexpression affects mitotic behavior of
tumor cells and genome instability. Additionally, we stu-
died whether replication stress can be targeted through
inhibition of the cell cycle checkpoint kinases WEE1
and ATR.
Results
Overexpression of cyclin E1 or Cdc25A leads to slower
replication kinetics and mitotic defects
Cyclin E1 is often found to be overexpressed in cancers,
specifically in TNBCs and high-grade ovarian cancers7,8,
which is accompanied by higher CCNE1 mRNA expres-
sion levels in these cancers (Supplementary Fig. 1A). To
study the effects of Cyclin E1 overexpression on replica-
tion kinetics, we engineered hTERT-immortalized human
retinal pigmented epithelial (RPE-1) cells to overexpress a
truncated oncogenic version of Cyclin E1 in a
doxycycline-dependent manner. Doxycycline treatment
resulted in a ~70-fold increased expression of Cyclin E1
compared to endogenous levels (Fig. 1a and Supplemen-
tary Fig. 1B). In parallel, we evaluated the effects of
Cdc25A overexpression, as this protein also leads to
CDK2 hyperactivation, albeit through an alternative
mechanism (Fig. 1a). To test whether overexpression of
Cyclin E1 or Cdc25A affected replication dynamics, cells
were treated with doxycycline for 48 h, and cells were
subsequently incubated with thymidine analogs CldU and
IdU to label ongoing replication (Fig. 1b). Single DNA
fibers were analyzed to measure replication kinetics. The
IdU fiber tract length was reduced by 28% in Cyclin E1-
overexpressing cells and 31% in Cdc25A-overexpressing
cells, indicating a robust reduction of ongoing DNA
synthesis speed compared to parental RPE-1-TP53wt cells
(Fig. 1c).
We next tested whether the observed replication stress
resulted in mitotic aberrancies. To this end, we quantified
the amount of chromatin bridges and lagging chromosomes
during anaphase and telophase at 48 h after induction of
Cyclin E1 or Cdc25A overexpression in RPE-1-TP53wt cells
(Fig. 1d). Doxycycline-induced Cyclin E1 or Cdc25A over-
expression resulted in a 3-fold increase in mitotic aber-
rancies when compared to control cells (Fig. 1e). Both
chromatin bridges and lagging chromosomes were
increased in Cyclin E1 and Cdc25A-overexpressing (Fig.
1e). A third type of mitotic aberration, ultra-fine bridges36,
was only increased in Cdc25A-overexpressing cells (26% vs.
14%) but not in Cyclin E1-overexpressing cells (11% vs.
14%) (Supplementary Fig. 1C). To further investigate the
mitotic aberrancies induced by oncogene-induced
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replication stress, RPE-1-TP53wt cells overexpressing Cyclin
E1 or Cdc25A were analyzed by live-cell microscopy. To
this end, cells were transduced with EGFP-tagged Histone-
H2B, treated with doxycycline to induce overexpression of
Cyclin E1 or Cdc25A and were then followed for the






































































































































































































































Fig. 1 (See legend on next page.)
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cell microscopy (Fig. 1f). Overexpression of Cyclin E1 or
Cdc25A did not significantly affect mitotic duration as
measured by the time between nuclear envelope break-
down (NEB) and anaphase entry (Fig. 1g), but did increase
the frequency of mitotic aberrancies (23% in Cyclin E1-
overexpressing cells and 19% in Cdc25A-overexpressing
cells vs. 12% and 3% in respective control-treated cells, Fig. 1h).
Combined, these data show that both Cyclin E1 and
Cdc25A-induced replication stress results in the forma-
tion of chromatin bridges and lagging chromosomes,
whereas Cdc25A overexpression also increases ultra-fine
bridge formation.
TP53 mutation exacerbates replication stress and mitotic
defects
Since oncogene expression in genomically instable
cancers is frequently associated with loss of TP53, we used
CRISPR/Cas9 to mutate TP53 in RPE-1 cells (Fig. 2a). We
selected two TP53-mutant clones and introduced the
doxycycline-inducible Cyclin E1 and Cdc25A constructs
or an empty vector to assess how p53-negative cells
behave upon overexpression of these oncogenes (Fig. 2b,
Supplementary Fig. 2A, B). Compared to endogenous
Cyclin E1 levels, doxycycline treatment increased the
expression by ~60-fold in clone #1 and ~38-fold in clone
#2 (Supplementary Fig. 2C). Like in TP53-wt cells, over-
expression of Cyclin E1 or Cdc25A in RPE-1-TP53−/−
cells reduced IdU tract length by 7–53% compared to
untreated conditions (Fig. 2c, Supplementary Fig. 2D).
We next analyzed the amounts of mitotic aberrancies.
In line with previous reports, RPE-1-TP53−/− cells
showed higher basal frequencies of mitotic aberrancies
when compared to RPE-1-TP53wt cells (17% vs. 4%, Figs.
1d and 2d, Supplementary Fig. 2E)37. The percentage of
mitotic aberrancies increased from 17% to 41.1% in Cyclin
E1-overexpressing cells and to 33.3% in Cdc25A-
overexpressing cells (Fig. 2d). We did not observe an
increase in the amount of ultra-fine bridges upon Cyclin
E1 or Cdc25A overexpression in TP53-mutated cells
(Supplementary Fig. 2F).
To confirm that the absence of p53 expression leads to
elevated amounts of mitotic defects, we analyzed H2B-EGFP-
expressing cells using live-cell imaging (Fig. 2e). Analogous to
previous observations in TP53wt cells, overexpression of
Cyclin E1 or Cdc25A in RPE-1-TP53−/−-H2B-EGFP cells did
not result in a significant change in the duration of mitosis
(Fig. 2f). We did observe more mitotic defects at baseline in
RPE-1-TP53−/− cells than in RPE-1-TP53wt cells (Figs. 1h
and 2e). Although not statistically significant, Cyclin E1 and
Cdc25A overexpression in TP53−/− cells did increase the
percentage of mitotic defects (Fig. 2g). These data underscore
that replication stress and mitotic errors are increased upon
TP53 inactivation, and point towards exacerbation of this
phenotype upon Cyclin E1 and Cdc25A overexpression.
Cyclin E1 or Cdc25A overexpression induces genomic
instability
Elevated levels of Cyclin E1 have previously been
associated to structural chromosome defects20,38.
Moreover, overexpression of both Cyclin E1 and
Cdc25A has been shown to result in loss of specific
genomic regions39–41. Furthermore, a mouse model of
Cyclin E1 overexpression resulted in tumors with
genomic instability42. Indeed, we also observed corre-
lations between mRNA expression of CCNE1 or
CDC25A and copy number load in various tumor types
(Supplementary Fig. 3A–C). However, since some of
these observations could be explained by indirect
effects, we employed single-cell whole genome sequen-
cing to assess if and how the observed chromosome
segregation defects upon short-term overexpression of
Cyclin E1 or Cdc25A in RPE-1-TP53−/− cells translate
into structural or numerical chromosome aberrations43.
Of note, we observed genomic deviations that arose in
the process of engineering the TP53−/− cell lines,
underscoring the importance of analyzing multiple
clones (Supplementary Fig. 4A). Importantly, we
observed increased numbers of focal copy number
alterations (CNAs) upon induction of Cyclin E1 or
Cdc25A overexpression for 5 days (Fig. 3a, b and
(see figure on previous page)
Fig. 1 Cdc25A or Cyclin E1 overexpression leads to replication stress. a RPE-1-TP53wt cells were engineered to overexpress empty, Cyclin E1 or
Cdc25A constructs in a doxycycline-inducible manner. Immunoblot shows Cyclin E1, Cdc25A, p53, and Vinculin protein levels at 48 h after addition of
doxycycline (dox). b Cells were treated with doxycycline for 48 h, were subsequently labeled for 20 min with CldU (25 µM) and for 20 min with IdU
(250 µM). Representative DNA fibers from doxycycline-treated cells are shown. Scale bar measures 10 µm. c Quantification of IdU DNA fiber lengths as
described in panel b. At least 266 fibers were analyzed. Graphs show individual data points, median and interquartile range. p-values were calculated
using the Mann–Whitney U test. d Examples of chromatin bridges and lagging chromosomes. Cells were stained with α-Tubulin (red) and
counterstained with DAPI (blue). Scale bar indicates 10 µm. e Quantification of anaphase and telophase cells containing chromatin bridges and/or
lagging chromosomes. The bars represent the mean and standard error or the mean (SEM) from three experiments, n > 25 per experimental
condition; p-values were calculated using two-tailed Student’s t-test. f Representative examples of mitotic aberrancies observed in RPE-1-TP53wt cells
transduced with H2B-EGFP using live-cell microscopy. Scale bar represents 20 µm. g Duration of mitosis as measured by nuclear envelope breakdown
to anaphase. Cells were pre-treated with doxycycline for 24 h and subsequently followed with live-cell microscopy using 7 min intervals for the
duration of 48 h. p-value was calculated using a Kruskal–Wallis test. h Quantification of aberrant mitoses in cells from panel h. p-values were
calculated using absolute values, using Mann–Whitney U test.
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Fig. 2 Mutation of TP53 exacerbates replication stress and mitotic defects. a Schematic overview of CRISPR/Cas9 gene targeting in TP53 gene.
The exon map and protein coding are based on Emsembl entry ENSG00000141510. Placement of the sgRNA sequence is indicated with a horizontal
line under exon 4 and the wild type sequence. Sanger sequencing shows that the gRNA targeting exon 4 induced a −7 bp deletion and a +215 bp
insertion in RPE-TP53−/− cl#1 and a −1 deletion and +2 insertion in RPE-TP53−/− cl#2, leading to frame-shifts in TP53. b RPE-1-TP53−/− cl#1 cells were
engineered to overexpress empty, Cyclin E1 or Cdc25A constructs in a doxycycline-inducible manner. Immunoblot shows Cyclin E1, Cdc25A, p53, and
Vinculin protein levels at 48 h after addition of doxycycline (dox). RPE-1-TP53wt cells were used as a positive control for p53. c Cells were treated with
doxycycline for 48 h, and were then labeled for 20min with CldU (25 µM) and subsequently for 20min with IdU (250 µM). Per condition at least 279
fibers were analyzed. Graphs show individual data points, median and interquartile range. p-values were calculated using the Mann–Whitney U test.
d Quantification of anaphase or telophase cells containing chromatin bridges or lagging chromosomes. The bars represent mean and standard error or
the mean (SEM) from three experiments, n > 25 per experimental condition; p-values were calculated using two-tailed Student’s t-test. e Representative
examples of mitotic aberrancies observed in RPE-1-TP53−/− cells transduced with H2B-EGFP cells using live-cell microscopy. Scale bar represents 20 µm.
f Duration of mitosis as measured by NEB breakdown to anaphase. Cells were pre-treated for 24 h with doxycycline and subsequently followed with
live-cell microscopy using 7min intervals for the duration of 48 h. p-value was calculated using a Kruskal–Wallis test. g Quantification of aberrant mitoses
in cells from panel f. p-values were calculated using absolute values, using Mann–Whitney U test.
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Supplementary Fig. 4B–D). This increase was statisti-
cally significant in RPE-1-TP53−/− clone #1, but not in
clone #2, possibly due to the limited number of cells that
were analyzed, a relatively short treatment time, and
lower levels of overexpression in clone #2 (Supple-
mentary Fig. 2C). In RPE-1-TP53−/− clone #1, Cyclin E1
overexpression resulted in more copy number aberra-
tions compared to empty vector control (Fig. 3b and
Supplementary Fig. 4C, whereas Cdc25A overexpression
resulted in more whole chromosome aberrations (Fig. 3c
and Supplementary Fig. 4D). These data suggest that the
increased mitotic errors upon Cyclin E1 or Cdc25A
overexpression translate into genomic instability.
Cyclin E1 and Cdc25A-induced mitotic aberrancies are
exacerbated upon treatment with ATR and WEE1 inhibitors
The observation that Cyclin E1 or Cdc25A over-















































































Fig. 3 Cyclin E1 or Cdc25A overexpression induces genomic instability. a Genome-wide copy number deviation plots of RPE-TP53−/− cl#1
empty (n= 47), RPE-TP53−/− cl#1 -Cyclin E1 (n= 44) and RPE-TP53−/− cl#1 -Cdc25A cells (n= 46). Cells were treated with doxycycline for 120 h. After
single cell sorting, genomic DNA was harvested for single-cell whole genome sequencing (sc-WGS). Each panel displays the individual cells in rows,
and the chromosomes numbers from 1-X in columns. The modal copy number state is pictured in green, deviations of the modal copy number state,
both focal and whole-chromosome, are colored red). b Copy-number alterations (CNAs) per cell were calculated according to the modal state.
Medians with interquartile range are depicted and statistical analyses were performed using a One-sided Mann–Whitney U test. c whole numerical
chromosomes per cell were counter per single cell. Medians with interquartile range are depicted and statistical analyses were performed using a
one-sided Mann–Whitney U test.





































































































































































































































































































































































































































































































































































Fig. 4 (See legend on next page.)
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and ensuing focal copy number alterations likely indicated
that replication-born DNA lesions remain unresolved
when cells enter mitosis. Indeed, regardless of TP53-sta-
tus, we observed that Cyclin E1-overexpressing cells, and
to a lesser extent Cdc25A-overexpressing cells have
increased amounts of the DNA damage marker pH2AX
Ser139 (γH2AX) (Fig. 4a, b, Supplementary Fig. 5A, B).
These cells also activated a replication stress response
mediated by ATR, as measured by pATR Thr1989,
pCHK1 Ser345, and pRPA32 Ser33 (Fig. 4a, b) and ele-
vated WEE1 activity as measured by levels of pCDK Tyr15
(Fig. 4c, d, Supplementary Fig. 5A, B). Although the
observed activation of the ATR and WEE1 kinases did not
completely prevent mitotic errors from occurring, inhi-
biting this response could enforce premature mitotic
entry44, thereby exacerbate chromosome segregation
errors in Cyclin E1-overexpressing or Cdc25A-
overexpressing cells. To test this, we induced over-
expression of Cyclin E1 or Cdc25A in RPE-1-TP53wt or
RPE-1-TP53−/− cells for 48 h, and subsequently treated
the cells with ATR or WEE1 inhibitors for 8 h. Upon
overexpression of Cyclin E1 in RPE-1-TP53wt cells, WEE1
inhibition, but not ATR inhibition, resulted in a significant
increase of mitotic aberrancies (Fig. 4f, g). In Cd25A-
overexpressing RPE-1-TP53wt cells, inhibition of ATR and
WEE1 both enhanced the frequency of mitotic aberrancies
(41.1–72.2% upon ATR inhibition and 25.6–77.8% upon
WEE1 inhibition, Fig. 4e, f).
In the RPE-1 TP53−/− clones, both ATR and WEE1
inhibition increased the frequency of mitotic aberrancies
in Cyclin E1-overexpressing cells (from 37.7% to 72.2%
upon ATR inhibition and up to 87.8% upon WEE1
inhibition, Fig. 4g, Supplementary Fig. 5C), and in
Cdc25A-overexpressing cells (from 37.7% to 81.1% upon
ATR inhibition and to 82.7% upon WEE1 inhibition, Fig.
4g) We did not observe an increase in ultra-fine bridges
upon inhibition of ATR or WEE1 in any of the tested
conditions (Supplementary Fig. 5D, E).
We next used live cell microscopy to investigate whe-
ther chromosome segregation defects induced by ATR or
WEE1-inhibition in Cyclin E1-overexpressing RPE-1-
TP53−/− cells translated into altered mitotic fidelity and
duration. Indeed, ATR inhibitor treatment in Cyclin E1-
overexpressing RPE-1-TP53−/− cells increased the per-
centage of mitoses with chromatin bridges from 13% to
33%, and increased the percentage of lagging chromo-
somes from 7% to 22% (Fig. 4g). Similarly, WEE1 inhibi-
tion exacerbated the formation of chromatin bridges in
Cyclin E1-overexpressing cells from 15% to 33% (Fig. 4g),
and increased the percentage of lagging chromosomes
from 9% to 14% (Fig. 4g). The induction of mitotic
aberration by ATR and WEE1 inhibition was confirmed in
RPE-1-TP53−/− H2B-EGFP using live cell microscopy
(Fig. 4h). ATR nor WEE1 inhibition affected mitotic
duration in Cyclin E-overexpressing cells (Supplementary
Fig. 5F). To measure premature mitotic upon ATR or
WEE1 inhibition, cells were synchronized using a double
thymidine block. In line with previous reports, ATR
inhibition accelerated entry into mitosis, leading to a
burst in mitotic cells44, whereas WEE1 inhibition did
not45 (Supplementary Fig. 5G). These data indicate that
ATR inhibition may affect mitotic fidelity by premature
mitotic entry, whereas the effects of WEE1 inhibition
appear more complex.
(see figure on previous page)
Fig. 4 ATR and WEE1 inhibition cause mitotic aberrancies. a, b RPE-TP53wt (panel a) and RPE-TP53−/− cl#1 (panel b) cells were treated with
doxycycline for 72 h to induce overexpression of Cyclin E or Cdc25A. Control cells (RPE-TP53wt) were then left untreated or were treated with ATR
inhibitor (ATRi, VE-822, 1 µM) for 2 h, followed by a 6 h treatment with hydroxyurea (HU, 1 mM) and immunoblotted for ATR-response proteins pATR,
pCHK1, pRPA, and γH2AX, and for WEE1-response marker pCDK (Tyr15). Vinculin serves as a loading control. c, d RPE-TP53wt (panel c) and RPE-TP53−/−
cl#1 (panel d) were treated with doxycycline for 72 h to induce overexpression of Cyclin E or Cdc25A. Control cells (RPE-TP53wt) were then left
untreated or were treated with ATR inhibitor (ATRi, VE-822, 1 µM) for 2 h, followed by a 6 h treatment with hydroxyurea (HU, 1 mM) and
immunoblotted for WEE1 response protein pCDK (Tyr15). e RPE-1-TP53wt cells induced to express Cyclin E1 or Cdc25A were treated with ATR inhibitor
(ATRi, VE-822, 0.25 µM) for 8 h as indicated. The percentages of anaphase or telophase cells containing chromatin bridges or lagging chromosomes
were quantified. The bars represent mean and standard error or the mean (SEM) from three experiments, n > 25 per condition; p-values were
calculated using two-tailed Student’s t-test. f RPE-1-TP53wt cells induced to express Cyclin E1 or Cdc25A were treated with WEE1 inhibitor (WEE1i, MK-
1775, 0.1 µM) for 8 h if indicated. The percentages of anaphase or telophase cells containing chromatin bridges or lagging were quantified. The bars
represent mean and SEM from three experiments, n > 25 per experimental condition; p-values were calculated using two-tailed Student’s t-test.
g RPE-1-TP53−/− cl#1 cells induced to express Cyclin E1 or Cdc25A were treated as in panels e and f. The percentages of anaphase or telophase cells
containing chromatin bridges or lagging chromosomes were quantified. The bars represent mean and SEM from three experiments, n > 25 per
experimental condition; The p-values were calculated by one-way ANOVA (p < 0.0001) and followed by Sidak’s multiple comparison test. h
Percentage of RPE-1-TP53−/− cl#1 -Cyclin E1-H2B-EGFP cells that showed aberrant mitoses. Cells were pre-treated for 24 h with doxycycline. Cells
were then treated with ATR inhibitor (VE-822, 0.25 µM) or WEE1 inhibitor (MK-1775, 0.1 µM), and subsequently followed with live-cell microscopy
using 7 min intervals for 48 h. p-values were calculated using a Mann–Whitney U test. i RPE-1-TP53wt and RPE-1-TP53−/− cl#1 cell lines were induced
to express Cyclin E1 or Cdc25A, and were treated for 3 days with ATR inhibitor (VE-822) in a range from 0 to 3.2 µM, or WEE1 inhibitor (MK-1775) in a
range from 0 to 1.28 µM. Subsequently, relative cell survival was assessed using MTT conversion as a proxy. Plots include mean and standard error of
the means (SEM) of three biological replicates. Reported p-values were calculated by a Student’s t-test comparing the area under the curve of
doxycycline-untreated samples to the curve of the doxycycline-treated samples.




















































































































































































































































































































































































































































Fig. 5 (See legend on next page.)
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Overexpression of cyclin E1 or Cdc25A results in increased
sensitivity to ATR and WEE1 inhibition
Using MTT assays, we next examined whether the
enhanced occurrence of mitotic aberrancies upon ATR or
WEE1 inhibition in Cyclin E1 or Cdc25A-overexpressing
cells is accompanied with increased sensitivity towards
ATR or WEE1 inhibition. In line with the absence of
increased mitotic aberrancies upon ATR inhibitor treat-
ment in TP53wt Cyclin E1-overexpressing cells, we
observed that Cyclin E1 overexpression only sensitized
RPE-TP53−/− cells to ATR inhibition (Fig. 4i), indicating
that loss of p53 function is required for ATR inhibitor
sensitivity in Cyclin E1-overexpressing cells. In contrast,
loss of p53 function was not required for WEE1 inhibitor
sensitivity in Cyclin E1-overexpressing cells, although it
did enhance sensitivity (Fig. 4i). Cdc25A overexpression
sensitized both RPE-1-TP53wt and RPE-1-TP53−/− cells
to ATR inhibition as well as to WEE1 inhibition (Fig. 4i).
These data indicate that Cyclin E1 or Cdc25A over-
expression sensitizes cells to inhibition of the ATR or
WEE1 checkpoint kinases.
Reduction of cyclin E1 levels diminishes replication stress
and mitotic errors
To test whether high expression levels of Cyclin E1
influenced DNA replication kinetics and sensitivity of
cancer cells to ATR and WEE1 inhibitor, we aimed to
downregulate Cyclin E1 expression in TNBC cancer cells.
We first tested the sensitivity to ATR and WEE1 inhibi-
tion in three TNBC cell lines (MDA-MB-157, HCC1806,
and HCC1569) that have a 19q12 amplification which
encompasses the CCNE1 gene46. HCC1806, and to a
lesser extent HCC1569, were sensitive to both ATR and
WEE1 inhibition (Supplementary Fig. 6A, B). MDA-MB-
157 cells did not display notable sensitivity to either drug
(Supplementary Fig. 6A, B), and we therefore selected
HCC1806 to test whether downregulation of CCNE1
could rescue the sensitivity to the cell cycle checkpoint
inhibitors. Two doxycycline-inducible shRNAs targeting
CCNE1 were transduced in these cells, and knockdown
efficiency was assessed after 48 h of doxycycline treatment
(Fig. 5a). Whereas shCCNE1#1 showed a near-complete
depletion of Cyclin E1, shCCNE1#2 reproducibly resulted
in a partial yet homogeneous knock-down throughout the
cell population (Fig. 5a–c). In line with Cyclin E1 being a
driver oncogene on the 19q12 amplicon, cell cycle analysis
demonstrated that severe depletion of Cyclin E1 levels
using shCCNE1#1 in HCC1806 cells reduced the per-
centage of cells in S-phase (Fig. 5d), which was accom-
panied by a near-complete loss of clonogenic potential
(Fig. 5e–g). In contrast, partial reduction of Cyclin E1
expression using shCCNE1#2 cells did not significantly
reduce the fraction of S-phase cells, nor did it compro-
mise clonogenic potential or colony size (Fig. 5d–g).
To evaluate the effects of Cyclin E1 downregulation on
replication kinetics, we analyzed DNA fibers of HCC1806
cells (Fig. 5h). Interestingly, knockdown of Cyclin E1 cells
resulted in increased DNA synthesis speed in HCC1806
cells, as judged by IdU tract length (Fig. 5i). In addition,
flow cytometry analyses demonstrated a reduction of
intensity of the DNA damage and replication stress
marker γH2AX upon Cyclin E1 knock-down (Fig. 5j). We
(see figure on previous page)
Fig. 5 Reducing Cyclin E1 overexpression diminishes replication stress and mitotic errors. a HCC1806 cells transduced with inducible Cyclin E1
construct (shCCNE1#1 or shCCNE1#2) or control shRNA (shLuc) were treated with doxycycline for 2 days, and immunoblotted for Cyclin E1 and
β-Actin. Cyclin E1 protein levels were measured and normalized to ‘shLuc -DOX’ controls for each experiment. Bar graphs reflect the average and
standard deviation from eight independent experiments. b Cyclin E1 knock-down after 2 days of doxycycline treatment assessed by
immunofluorescence microscopy. The white lines indicate boundaries of nuclei based on DAPI counterstaining. c Average staining intensity of Cyclin
E1 as shown in panel b was categorized and plotted in a histogram. The curve fitted is a log-normal Gaussian distribution. At least 450 nuclei were
measured. d Percentage of EdU-positive cells after 48 h of doxycycline treatment, measured by flow cytometry. e Representative pictures of
clonogenic survival of HCC1806 cells. Cells were plated in six-well plates and allowed to attach for 24 h, after which doxycycline was added. After
14 days, surviving colonies were stained. f, g Colony survival percentages compared to Luc-dox controls f and relative average diameter of colonies
counted g in panel f, relative to Luc-dox control. Bars represent the mean and standard error of the mean (SEM) mitotic fraction of two independent
experiments. p-values were calculated using two-tailed Student’s t-test h cells were treated with doxycycline for 48 h and sequentially labeled for
20 min with CldU (25 µM) and 20min with IdU (250 µM). Representative DNA fibers of doxycycline-treated samples are shown. i Quantification of IdU
DNA fiber lengths as described in panel h. Per condition, at least 466 fibers were analyzed and corresponding medians with interquartile range are
shown. p-value was calculated using Mann–Whitney U test. j γH2AX intensity as measured by flow cytometry in cells treated with and without
doxycycline for 48 h. Means and SEM normalized to the untreated luciferase condition are shown from three biological replicates. k Cyclin E1 knock-
down was induced by doxycycline treatment for 48 h. Cells were then fixed and the percentage of mitotic aberrancies was quantified. Data
represents mean and SEM of three independent experiments; at least 30 mitoses were analyzed for each experimental condition. The p-values were
calculated by one-way ANOVA (p < 0.0001) and followed by Sidak’s multiple comparison test. l Duration of mitosis as measured by NEB breakdown to
anaphase. HCC1806 H2B-EGFP cells were pre-treated for 48 h with doxycycline and subsequently followed with live-cell microscopy in 7 min intervals
for the duration of 48 h. p-value was calculated using a Kruskal–Wallis test. and subsequently followed with live-cell microscopy using 7 min intervals
for 48 h. Duration of mitosis is shown.m Quantification of aberrant mitoses in cells from panel l. p-values were calculated using absolute values, using
Mann–Whitney U test.
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next tested whether the observed reduction of repli-
cation stress levels in the Cyclin E1 knock-down cells
also resulted in a reduction of mitotic aberrancies. Of
note, the base-line frequency of mitotic errors in
untreated HCC1806-shLuc cells was ~50% (Fig. 5k),
which is 10-fold higher than in non-transformed RPE-
1-TP53wt cells (Fig. 1e). Partial depletion of Cyclin E1
resulted in a dramatic reduction of mitotic errors to
~20% (Fig. 5k). Live-cell microscopy demonstrated that
while mitotic duration was similar in all conditions
(Fig. 5l), the percentage of mitotic errors is reduced
~1.5-fold (Fig. 5m). Combined, our data show that
reducing Cyclin E1 expression levels in a Cyclin E1-
overexpressing TNBC model, reduces replication stress
levels and mitotic errors.
ATR and WEE1 inhibitor sensitivity in cyclin E1-
overexpressing cells
We next investigated how downregulation of Cyclin E1
impacts on replication stress and ATR and WEE1 inhibitor
sensitivity. ATR or WEE1 inhibition increased γH2AX
intensity levels (Supplementary Fig. 6C, D), although levels
of mitotic errors were not further increased, likely because
of the high base-line levels of mitotic errors in the
HCC1806 cell (Supplementary Fig. 6E). Importantly, partial
Cyclin E1-depletion consistently lowered γH2AX inten-
sities and mitotic aberrancies observed in ATR or WEE1
inhibitor-treated cells (Supplementary Fig. 6E). Moreover,
treatment with ATR and WEE1 inhibitor increased the
mitotic fraction of HCC1806 cells ~2-fold, which was

































































































































































































































































































Fig. 6 Cyclin E1 overexpression is required for ATR and WEE1 inhibitor sensitivity. a HCC1806 cell lines were induced to express Cyclin
E1 shRNA for 2 days and were then treated with 0.25 µM of ATR inhibitor (ATRi, VE-822) or 0.1 µM of WEE1 inhibitor (WEE1i, MK-1775) for 8 h. Cells
were then fixed and stained for DNA content (propidium iodine) and for mitotic population (MPM2) and analyzed using flow cytometry. Bars
represent the mean and standard error of the mean (SEM) mitotic fraction of four independent experiments, normalized to untreated Luc-dox; p-
values were calculated using two-tailed Student’s t-test b, c HCC1806 cell lines were induced to express Cyclin E1 shRNA and were subsequently
treated for 3 days with ATR inhibitor (ATRi, VE-822) (panel b) or WEE1 inhibitor (WEE1i, MK-1775) (panel c) in a range from 0 to 1.28 µM. Subsequently,
relative cell survival was assessed using MTT conversion as a proxy. Averages and standard error of the means (SEM) of three biological replicates are
plotted. Reported p-values were calculated by a Student’s t-test comparing the area under the curve of doxycycline untreated samples to the curve
of the doxycycline-treated samples. d Doxycycline-inducible HCC1806 cells were plated in six-well plates and allowed to attach for 24 h.
Subsequently, cells were treated with doxycycline and 0.05 µM of ATR inhibitor (ATRi, VE-822) or 0.08 µM of WEE1 inhibitor (WEE1i, MK-1775). After
11 days, surviving colonies were stained. e Quantification of clonogenic survival from panel d. Bars represent the mean and SEM of clonogenic
survival, relative to the non-doxycycline treated controls of two independent experiments; p-values were calculated using two-tailed Student’s t-test.
f Quantification of colony diameter, relative to non-treated shLuc cells of two independent experiments. Bars represent mean and SEM; p-values were
calculated using two-tailed Student’s t-test.
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Moreover, we observed Cyclin E1 depletion to confer
resistance to ATR or WEE1 inhibition (Fig. 6b, c). Simi-
larly, partial Cyclin E1 knockdown using shCCNE1#2
resulted in increased clonogenic survival of WEE1
inhibitor-treated HCC1806 cells (Fig. 6d–f). Combined,
our data indicate that Cyclin E1 overexpression is not only
sufficient to drive sensitivity to ATR and WEE1 inhibition,
but is also required for these effects.
Discussion
In this report, we investigated the effects of oncogene-
induced replication stress on mitotic fidelity and on the
sensitivity to cell cycle checkpoint kinase inhibitors. We
demonstrated that overexpression of Cdc25A or Cyclin
E1 resulted in severe replication stress, which was asso-
ciated with the induction of chromatin bridges and lag-
ging chromosomes during mitosis. Furthermore, we
observed that oncogene-induced replication stress sensi-
tized cells to ATR and WEE1 checkpoint kinase inhibi-
tors. ATR and WEE1 inhibition exacerbated the mitotic
aberrancies induced by Cyclin E1 or Cdc25A over-
expression and increased cell death. Finally, we show
downregulation of Cyclin E1 in TNBC cells to result in
rescue of replication kinetics and reduced cytotoxicity of
ATR and WEE1 inhibitors.
Our findings are in line with earlier reports in which
ATR inhibitor sensitivity was associated with Cdc25A
expression, and WEE1 inhibitor sensitivity was associated
with Cyclin E expression47,48. Importantly, our data point
towards a critical role for mitotic segregation defects in cell
death following oncogene-induced replication stress. Fur-
thermore, our data indicate that exacerbation of chromo-
some segregation defects during mitosis upon ATR and
WEE1 inhibit is associated with cytotoxicity of these drugs
in cells harboring oncogene-induced replication stress,
which was previously reported for PARP inhibitors32.
A possible explanation for these observations is that
acceleration of mitotic entry upon ATR and WEE1 inhi-
bition, leaves cells with oncogene-induced replication
stress with insufficient time to resolve replicative lesions.
Subsequently, mitotic entry commences in the presence
of severe DNA lesions, which precludes proper chromo-
some segregation and leads to cell death. Indeed, cells in
which ATR or WEE1 inhibition induced mitotic chro-
mosome segregation defects showed a proportional
increase in inhibitor-induced cytotoxicity. Specifically,
RPE-1 cells with Cdc25A overexpression showed more
chromosomal segregation defects and sensitivity to ATR
and WEE1 inhibition in both TP53wt and TP53−/− set-
tings. Conversely, Cyclin E1-overexpressing cells were
only sensitive to both agents when TP53 was mutated.
These observations are in good agreement with a role for
p53 signaling in preventing genomic instability following
Cyclin E1 amplification6,18–20.
An explanation for why Cdc25A-overexpressing cells
are sensitive to ATR and WEE1 inhibitors in a TP53 wild-
type setting could lie in checkpoint abrogation resulting
from Cdc25A overexpression49. Furthermore, whereas
Cyclin E1 overexpression only leads to CDK2 activation,
Cdc25A affects multiple CDKs, including CDK130. As a
consequence, Cdc25A amplification de-regulates both S-
phase and G2/M progression49. Interestingly, our study
demonstrates that WEE1 inhibition sensitizes tumor cells
regardless of TP53 mutations status. WEE1 inhibition was
reported earlier to be primarily effective in TP53 mutant
cells50, which was attributed to a defective G1/S check-
point in TP53 mutant cells, leading to increased reliance
on their G2/M checkpoint. However, recent reports have
shown that TP53 mutation status alone does not explain
responses of tumors to WEE1 inhibition, which under-
score that WEE1 inhibitor sensitivity is more complex and
multifactorial45,48,51.
As overexpression of Cyclin E1 leads to replication
stress, increased mitotic aberrancies, and sensitivity to
inhibition of ATR or WEE1, we wondered whether nor-
malization of Cyclin E1 levels in TNBC cells harboring
CCNE1 amplification reduced these effects46. We
observed that downregulation of Cyclin E1 resulted in
elevated DNA replication speed, and diminished cytotoxic
effects of ATR or WEE1 inhibition. These findings are in
line with previous observations that Cyclin E1 over-
expression contributes to the increased origin initiation
and collisions between the replication and transcription
machineries, which negatively impact replication speed
and lead to replication fork collapse17,42. Such lesions
create a dependence on replication checkpoint signaling,
and explain the sensitivity of Cyclin E1-overexpressing
cells to ATR and WEE1 inhibitors48,52, as well as the
reversal of ATR and WEE1 inhibitor sensitivity upon
Cyclin E1 downregulation.
Our data supports the notion that expression of repli-
cation stress-inducing oncogenes could be used as criteria
to select patients for treatment with replication check-
point kinase inhibitors, including ATR and WEE1. To test
their value as biomarkers, it would be insightful to test
ATR and WEE1 sensitivity in tumors harboring amplifi-
cations of different replication stress-inducing oncogenes,
including CCNE153, which is being used in a clinical trial
to select patients for WEE1 inhibitor treatment (clin-
icaltrials.gov identifier: NCT03253679). In this context,
cancers that currently lack drug targets are of particular
interest, as these are difficult to treat, including triple-
negative breast cancer.
Taken together, this study reports that replication stress
induced by overexpression of Cyclin E1 and Cdc25A
results in the formation of lagging chromosomes and
chromatin bridges, which is further exacerbated by inhi-
bition of ATR or WEE1 kinases, and results in
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exacerbated tumor cell killing. Conversely, normalization
of Cyclin E1 levels restores replication kinetics and
reduces the cytotoxicity from inhibition of ATR or WEE1
kinases. These insights could therefore help to guide novel
treatment strategies for targeting genomically instable
tumors harboring oncogene amplifications.
Materials and methods
Cell lines
hTERT-immortalized human RPE-1, human embryonic
kidney 293 (HEK293T), HCC1806, HCC1569, and MDA-
MB-157 cell lines were obtained from the American Type
Culture Collection (#CRL4000, #CRL3216, #CRL2335,
#CRL2330, and #HTB24) and regularly checked for
mycoplasma and authenticated using STR profiling. RPE-
1, HEK293T, and MDA-MB-157 cells were cultured in
Dulbecco’s minimum essential media (DMEM, Thermo-
fisher), complemented with 10% (v/v) fetal calf serum
(FCS), 1% penicillin, and 1% streptomycin (Gibco).
HCC1806 and HCC1569 cells were maintained in Roswell
Park Memorial Institute medium (RPMI, Thermofisher)
complemented with 10% FCS and 1% penicillin/strepto-
mycin. All cells were grown at 37 °C in 20% O2 and 5%
CO2 in a humidified incubator.
Mutagenesis
CRISPR/Cas9 was used to mutate TP53 in RPE-1 cells.
To this end, a single guide RNA (sgRNA) (5′-CTGT
CATCTTCTGTCCCTTC-3′) targeting exon 4 was cloned
into pSpCas9(BB)-2A-GFP, which was provided by Feng
Zhang (PX458, plasmid #48138, Addgene)54. Next, RPE-1
cells were transfected with PX458 and selected with
Nutlin-3a (Axon Medchem, 10 μM) for 3 weeks. The
viable cells were sorted into monoclonal lines using a
MoFLO XDP or Sony cell sorter. TP53 mutations in exon
4 were confirmed by Sanger sequencing and lack of p53
expression was confirmed by Western blot analysis. The
reading frame of TP53 was shifted by a 7 basepair deletion
and a +217 bp insertion in Clone#1 and a −1 deletion and
a +2 insertion in Clone#2 (Fig. 2a).
DNA cloning and retroviral infections
RPE-1-TP53wt and RPE-1-TP53mut cell lines were
engineered to express Cdc25A or Cyclin E1 in a
doxycycline-dependent manner. To this end, human
CDC25A was PCR amplified from FLAG-CDC25A-WT,
which was a gift from Peter Stambrook55, using the fol-
lowing oligos: forward: 5′-CGCGGCCGCCATGGAACT
GGGCCCGGAGCCC-3′, reverse: 5′-GATGAATTCTCA
CAGCTTCTTCAGACG-3′. Human CCNE1 was PCR
amplified from Rc-CycE, which was a gift from Bob
Weinberg (Plasmid #8963, Addgene)56, using the follow-
ing oligos: forward: 5′-CGCGGCCGCCATGAAGGAG
GACGGCGGCGCG-3′, reverse: 5′-GATGAATTCTCAC
GCCATTTCCGGCCC-3′. The resulting fragments were
cloned into pJET1.2/blunt, GeneJET (ThermoFisher).
CDC25A and CCNE1 were subcloned into pRetroX-
Tight-Pur using NotI and EcoRI restriction sites. Subse-
quently, cell lines harboring pRetroX-Tet-On Advanced
were transduced with pRetroX-Tight-Pur containing
CDC25A, CCNE1, or empty plasmid. For transduction,
HEK293T cells were transfected with 10 µg of pRetroX-
Tet-On Advanced, 2.5 µg of pMDg, and 7.5 µg of pMDg/p
as described previously57. After transduction, RPE-1 cell
lines were selected for 7 days using geneticin (G418 Sul-
fate, 800 µg/mL, Thermofisher). Next, cell lines harboring
pRetroX-Tet-On Advanced were transduced with
pRetroX-Tight-Pur vectors containing CDC25A or
CCNE1, and selected for 2 days with puromycin dihy-
drochloride (5 µg/mL, Sigma). To obtain cells stably
expressing Histone H2B-EGFP, indicated RPE-1 cell lines
were transduced as previously described32.
RNA interference
For identifying endogenous Cyclin E1 on immunoblots,
a SMARTpool siRNA mix (Dharmacon, Horizon Inspired
Cell Solutions) for CCNE1 was transfected at a final
concentration of 80 nM with Oligofectamine (Invitrogen)
according to the manufacturer’s instructions. To down-
regulate CCNE1 in HCC1806 cells, lentiviral shRNA
interference sequences were clones into the Tet-pLKO-
puro plasmid (a gift from Dimitri Wiederschain, #21915,
Addgene58), following the depositor’s protocol.
shCCNE1#1 was designed to target exon 8 (5′-GCTT
GTTCAGGAGATGAAATT-3′) and shCCNE1#2 (sh#2)
was designed to target exon 7 (5′-CGGTATATGGCGAC
ACAAGAA-3′). A control shRNA-targeting luciferase (5′- A
GAGCTGTTTCTGAGGAGCC-3′) was included in the
experiments.
Western blotting
After pretreatment with doxycycline, ATR inhibitor VE-
822 (Axon), WEE1 inhibitor MK1775 (Axon MedChem),
or Hydroxyurea (Sigma) at the indicated doses, cells were
washed in PBS and lysed in MPER lysis buffer (Pierce),
complemented with protease and phosphatase inhibitor
cocktail (Thermo Scientific). Protein concentration was
quantified using the Pierce BCA Protein Quantification
Kit (Thermo Scientific). Lysates were resolved by
SDS–polyacrylamide gels and transferred to poly-
vinylidene fluoride (PVDF) membranes (Immobilon).
Membranes were incubated overnight at 4 °C with pri-
mary antibodies in Tris-buffered saline (Tris) containing
0.05% Tween-20 (Sigma) with 5% skimmed milk (Sigma).
The following primary antibodies were used for Western
blot analysis: mouse anti-Cdc25A (Santa Cruz Bio-
technology, Sc-7389, 1:500), mouse anti-Cyclin E1
([HE12], Abcam, ab3927, 1:1000), mouse anti-p53 ([DO-
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1], Santa Cruz Biotechnology, Sc-126, 1:1000), rabbit-anti-
vinculin ([EPR8185], Abcam, ab129002, 1:2500), rabbit-
anti-phospho ATM/ATR (Thr1989) Merck Millipore
ABE462, 1:500), rabbit-anti-Phospho-Chk1 (Ser345)
([133D3], Cell Signaling, #2348, 1:500), Rabbit anti-
phospho RPA32 (S33) (Bethyl Laboratories 1:1000),
rabbit-anti-Phospho-Histone H2AX (Ser139) ([20E3],
Cell Signaling, #9718, 1:1000), rabbit-anti-Recombinant
Anti-CDK1+CDK2+CDK3+CDK5 (phospho Y15)
([EPR7875], Abcam, ab133463, 1:1000) and mouse anti-
beta-actin (MpBiomedicals, 69100, 1:10,000). Subse-
quently, membranes were incubated with corresponding
horseradish peroxidase-conjugated secondary antibodies
(1:2000, DAKO), and visualized with Lumi-Light (Roche
Diagnostics). Images were captured with the ChemiDoc
MP imaging system (Bio-Rad), and analyzed with the
analyze gel module of the FIJI software.
Flow cytometry
Flow cytometry was performed as described in ref. 44.
Cells were stained with MPM2 antibody (Merck Mil-
lipore, 05-368, 1:000) and anti-γH2AX (Cell Signaling,
#9718, 1:200), in combination with Alexa-488-
conjugated and Alexa-647-conjugated secondary anti-
bodies (1:200).
Single-cell whole-genome analysis
RPE-1-TP53-wt cells and RPE-1-TP53−/− cell lines har-
boring doxycycline-inducible Cdc25A or Cyclin E1 were
treated with doxycycline (1 µg/ml) for 120 h. Single-cell
sequencing was performed as described in refs. 43,44.
MTT assays
RPE-1-TP53wt or RPE-1-TP53−/− cell lines harboring
doxycycline-inducible Cdc25A or Cyclin E1 were left
untreated or treated with doxycycline (1 µg/ml) for 48 h.
Subsequently, cells were re-plated in 96-wells at 10,000
cells per well in the continued presence or absence of
doxycycline, and allowed to attach for 24 h. ATR inhi-
bitor VE-822 (Axon) or WEE1 inhibitor MK-1775 (Axon
MedChem) was added at indicated concentrations for
3 days. Next, cells were incubated with methylthiazol
tetrazolium (MTT, final concentration 0.5 mg/ml) for
4 h. After removal of medium, formazan crystals were
dissolved in dimethyl sulfoxide (DMSO). Absorbance
was measured at 520 nm, and was quantified using a
Benchmark III spectrophotometer (Bio-Rad). MTT
conversion was plotted relative to the untreated cells.
Per experiment, six technical replicates per condition
were included. Averages and standard error of the means
(SEM) of three biological replicates are plotted. The area
under the curve was determined by Graphpad Prism 8
and used to test for statistical significance using a Stu-
dent’s t-test.
Live-cell microscopy
RPE-1-TP53wt or RPE-1-TP53−/− cell lines harboring
doxycycline-inducible Cdc25A or Cyclin E1, transduced
with H2B-EGFP were seeded in eight-chambered cover
glass plates (Lab-Tek-II, Nunc). Cells were left untreated
or treated with doxycycline (1 µg/ml) for 24 h, and were
subsequently imaged for 48 h under the same treatment
on a Delta Vision Elite microscope (×20 objective with
0.75 NA). Every 7 min, 10–15 images in the Z-plane were
acquired with an interval of 0.5 µm. Mitotic entry was
defined by NEB, and mitotic duration was defined as time
between NEB and anaphase entry. Image analysis was
done with SoftWorX software (Applied Precision/GE
Healthcare).
Detailed descriptions of the following techniques are
available in the Supplemental methods.
● DNA fiber analysis
● Immunofluorescence microscopy
● Flow cytometry
● Single-cell whole-genome analysis
● Clonogenic survival assays
● TCGA data set and CNA burden
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